SynAct Pharma Announces Positive Interim Phase 2 Data of AP1189 in Rheumatoid Arthritis
· The Data Safety Monitoring Board (DSMB) finds no safety concerns in the 50 mg and 100 mg dose cohorts · Signs of efficacy against rheumatoid arthritis was observed. Thus, the number of patients changing from the severe to the moderate Clinical Disease Activity Index (CDAI) score was higher than placebo in both treatment groups in a dose dependent manner · The DSMB recommends that the study continues to Part 2 in which the patients are randomized to 50 mg AP1189, 100 mg AP1189 and placebo plus methotrexate (MTX) · Full Phase 2 topline data is expected by the end of Q2 2021Lund,